EGFR and glioblastoma: Osimertinib is a third-generation EGFR inhibitor demonstrated to have superior potency for inhibiting EGFRvIII activity.220,221 Osimertinib has not been explored in clinical trials of glioblastoma patients, however, a retrospective study of 15 recurrent glioblastoma patients treated with osimertinib and bevacizumab reported a 6-month PFS rate of 46%.222 A case report of a woman diagnosed with glioblastoma who had progressive disease after attempts at RT/TMZ, surgery, and bevacizumab was given osimertinib in an off-label, off-protocol manner.